Development of novel nanoparticles for DDS, and establishment of Therapeutic modality for brain ischemia by use of these nanoparticles.

脑缺血/再灌注损伤是再灌注后发生的继发性损伤。我们先前已经阐明，脂质体DDS能够在再灌注后通过破坏的血脑屏障将某些药物输送到缺血部位。因此，我们选择了两种具有神经保护作用的药物，去唾液酸促红细胞生成素和FK506，尝试将它们脂质体，并考察其有效性。本工作的目的是开发一种治疗脑缺血再灌注损伤的新型DDS药物。

Brain ischemia/reperfusion injury is a secondary injury occurring after reperfusion. We previously clarified that liposomal DDS enables the delivery of certain drugs to the ischemic site through the disrupted blood-brain barriers after reperfusion. Therefore, we selected two kinds of agents having neuroprotective effect, asialoerythropoietin and FK506, attempted to liposomalize them, and examined the usefulness. The aim of this work is to develop a novel DDS durgs for the treatment of brain ischemia/reperfusion injury.